Pale Fire Capital SE Makes New $216,000 Investment in Harrow, Inc. $HROW

Key Points

• Pale Fire Capital SE acquired 8,133 shares of Harrow, Inc. valued at approximately $216,000 during the first quarter, reflecting growing interest from institutional investors as they own 72.76% of the company's stock.
• Analysts are optimistic about Harrow, with multiple upgrades including a "strong-buy" rating from Zacks Research and a target price increase from various firms, setting a consensus target at $64.67.
• Harrow reported an EPS of $0.24 in its latest quarterly earnings, significantly exceeding expectations, although the company's revenue was slightly below consensus estimates.

Pale Fire Capital SE bought a new stake in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 8,133 shares of the company's stock, valued at approximately $216,000.

Other hedge funds also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new position in Harrow during the 4th quarter valued at about $25,000. Tower Research Capital LLC TRC increased its position in Harrow by 769.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock valued at $55,000 after buying an additional 1,462 shares in the last quarter. Aquatic Capital Management LLC acquired a new position in Harrow during the 4th quarter valued at about $78,000. GAMMA Investing LLC increased its position in Harrow by 2,401.2% during the 1st quarter. GAMMA Investing LLC now owns 6,278 shares of the company's stock valued at $1,670,000 after buying an additional 6,027 shares in the last quarter. Finally, Rafferty Asset Management LLC acquired a new position in Harrow during the 4th quarter valued at about $270,000. 72.76% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

HROW has been the topic of several recent analyst reports. Cantor Fitzgerald initiated coverage on Harrow in a research report on Friday, July 11th. They set an "overweight" rating and a $76.00 target price on the stock. HC Wainwright upped their target price on Harrow from $60.00 to $64.00 and gave the company a "buy" rating in a research report on Wednesday, August 13th. BTIG Research upped their target price on Harrow from $62.00 to $63.00 and gave the company a "buy" rating in a research report on Thursday, August 14th. William Blair started coverage on Harrow in a research note on Tuesday, June 10th. They issued an "outperform" rating on the stock. Finally, Zacks Research upgraded Harrow from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $64.67.

Harrow Price Performance

HROW stock traded up $1.21 during mid-day trading on Tuesday, reaching $38.57. 413,881 shares of the company's stock were exchanged, compared to its average volume of 677,412. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -154.28 and a beta of 0.41. The stock's 50 day moving average is $34.21 and its 200 day moving average is $29.25. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.62 and a quick ratio of 0.58. Harrow, Inc. has a 12-month low of $20.85 and a 12-month high of $59.23.

Harrow (NASDAQ:HROW - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.01 by $0.23. The company had revenue of $63.74 million for the quarter, compared to the consensus estimate of $64.23 million. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%. Harrow has set its FY 2025 guidance at EPS. On average, research analysts expect that Harrow, Inc. will post -0.53 EPS for the current year.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.